Changchun High-Tech Receives Acceptance Notice for Clinical Trial Application of RSV Antibody Combination Injection

Stock News

Sep 22

Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that its subsidiary, Changchun Baike Biological Technology Co., Ltd. ("Baike Bio"), recently received the "Acceptance Notice" from the National Medical Products Administration for the clinical trial application of the recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination preparation (referred to as "RSV antibody").

The RSV antibody accepted this time is intended to prevent lower respiratory tract infections caused by RSV in newborns and infants. Preclinical in vivo and in vitro pharmacodynamic studies indicate that the product demonstrates good efficacy; preclinical toxicology studies show that the product is generally well-tolerated and has a manageable safety profile. Additionally, a single administration can cover an entire RSV epidemic season, enhancing patient compliance and the convenience of prevention.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/news/1181632018"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181632018\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181632018?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-22 20:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181632018","market":"hk","top_or_hot":-1,"title":"Changchun High-Tech Receives Acceptance Notice for Clinical Trial Application of RSV Antibody Combination Injection","media":"Stock News","content":"<p><b>Changchun High-Tech Industry (Group) Co.,Ltd.</b> (000661.SZ) announced that its subsidiary, Changchun Baike Biological Technology Co., Ltd. (\"Baike Bio\"), recently received the \"Acceptance Notice\" from the National Medical Products Administration for the clinical trial application of the recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination preparation (referred to as \"RSV antibody\").<br><br>The RSV antibody accepted this time is intended to prevent lower respiratory tract infections caused by RSV in newborns and infants. Preclinical in vivo and in vitro pharmacodynamic studies indicate that the product demonstrates good efficacy; preclinical toxicology studies show that the product is generally well-tolerated and has a manageable safety profile. Additionally, a single administration can cover an entire RSV epidemic season, enhancing patient compliance and the convenience of prevention.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Changchun High-Tech Receives Acceptance Notice for Clinical Trial Application of RSV Antibody Combination Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChangchun High-Tech Receives Acceptance Notice for Clinical Trial Application of RSV Antibody Combination Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-22 20:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Changchun High-Tech Industry (Group) Co.,Ltd.</b> (000661.SZ) announced that its subsidiary, Changchun Baike Biological Technology Co., Ltd. (\"Baike Bio\"), recently received the \"Acceptance Notice\" from the National Medical Products Administration for the clinical trial application of the recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination preparation (referred to as \"RSV antibody\").<br><br>The RSV antibody accepted this time is intended to prevent lower respiratory tract infections caused by RSV in newborns and infants. Preclinical in vivo and in vitro pharmacodynamic studies indicate that the product demonstrates good efficacy; preclinical toxicology studies show that the product is generally well-tolerated and has a manageable safety profile. Additionally, a single administration can cover an entire RSV epidemic season, enhancing patient compliance and the convenience of prevention.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0075","symbol_name":"新三板","start_time":0,"source_url":"","article_id":"1181632018","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181632018","pubTimestamp":1790080464,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that its subsidiary, Changchun Baike Biological Technology Co., Ltd. (\"Baike Bio\"), recently received the \"Acceptance Notice\" from...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0075":"新三板","MDTX":"Corgi MediaTek 2x Daily ETF","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BK0057":"长吉图板块","BK0188":"融资融券","000661":"长春高新","BK0028":"国家队","BK0239":"医药制造","BK0046":"生物疫苗","PSYK":"PSYK ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","BMED":"iShares Health Innovation Active ETF"},"translate_title":"长春高新收到RSV抗体组合注射液临床试验申请受理通知书","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSYK":1,"IBBJ":1,"BMED":1,"IBBQ":1,"MDTX":1,"000661":1},"content_text":"Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that its subsidiary, Changchun Baike Biological Technology Co., Ltd. (\"Baike Bio\"), recently received the \"Acceptance Notice\" from the National Medical Products Administration for the clinical trial application of the recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination preparation (referred to as \"RSV antibody\").The RSV antibody accepted this time is intended to prevent lower respiratory tract infections caused by RSV in newborns and infants. Preclinical in vivo and in vitro pharmacodynamic studies indicate that the product demonstrates good efficacy; preclinical toxicology studies show that the product is generally well-tolerated and has a manageable safety profile. Additionally, a single administration can cover an entire RSV epidemic season, enhancing patient compliance and the convenience of prevention.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}